Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7394MR)

This product GTTS-WQ7394MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7394MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12707MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ15MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ14540MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ6842MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ6122MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ15667MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ12226MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ2535MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW